Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but filing text confirms "Synthetic Blood International, Inc.")
Reporting Period: Quarterly period ended October 31, 1999 (Six months ended October 31, 1999).
Status: Development Stage Company in pre-clinical trial stage.
Going Concern: Substantial doubt exists regarding the company's ability to continue as a going concern due to accumulated losses of $10.8 million and a working capital deficit of $328,446. Continuation depends on obtaining additional financing and FDA approval.
Key Financial Metrics
| Metric | Three Months Ended Oct 31, 1999 | Six Months Ended Oct 31, 1999 | Balance Sheet (Oct 31, 1999) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(178,216) | $(398,573) | Accumulated Deficit: $(10,800,572) |
| Total Expenses | $203,576 | $424,674 | N/A |
| Cash and Equivalents | N/A | N/A | $206,920 |
| Working Capital | N/A | N/A | Deficit of $(328,446) |
| Total Liabilities | N/A | N/A | $583,440 |
| Shares Outstanding | N/A | N/A | 69,509,788 |
Material Changes vs. Prior Period
- Expense Reduction: Total expenses decreased by approximately $38,000 for the three months and $51,000 for the six months compared to the prior year periods.
- R&D Expenses: Decreased to $26,545 (3-month) and $70,243 (6-month) due to reductions in contract wages, laboratory rent, and equipment rental.
- Other Income: Increased by $25,000 due to a vendor settlement, partially offsetting the net loss.
- Financing Activity: Significant cash inflow from financing activities ($8.4 million net for 6 months) driven by the sale of common stock ($6.86 million) and proceeds from notes ($951k).
- Stock Issuance: Issued 3,450,710 shares at $0.08/share and 9,000,000 shares at $0.13/share (in exchange for a $1.2M promissory note) during the quarter.
Outlook, Risks, and Management Commentary
- Capital Requirements: Additional funding is critical to proceed with Phase I, II, and III human testing. Management is pursuing strategic alliances and joint ventures to share development costs.
- Regulatory Risk: No assurance that FDA approval will be granted. Products are currently in pre-clinical stages.
- Operational Risks: Risks include inability to secure financing, failure of clinical trials, patent infringement issues, and difficulties in scaling manufacturing.
- Year 2000 Compliance: Management believes internal systems are compliant, but risks remain regarding supplier and vendor infrastructure failures potentially causing R&D delays.
- Unusual Items: The $1.2 million stock subscription receivable is recorded as a reduction of Stockholders' Deficiency, pending payment via a promissory note.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure immediate financing to cover the $328,446 working capital deficit and fund future clinical trials.
- Stock Subscription Receivable: Confirm the status of the $1.2 million promissory note issued for 9 million shares; this is a significant asset on the balance sheet contingent on future payments.
- Regulatory Milestones: Assess the timeline and probability of moving from pre-clinical to FDA-approved clinical trials.
- Dilution Risk: Review the impact of recent and potential future equity issuances (69.5 million shares outstanding) on shareholder value.
- Vendor Settlement: Verify the nature and sustainability of the $25,000 vendor settlement recorded as other income.